CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
AuthorXuan, J; Pearson, RB; Sanij, E
Source TitleMolecular and Cellular Oncology
PublisherTAYLOR & FRANCIS INC
AffiliationSir Peter MacCallum Department of Oncology
Document TypeJournal Article
CitationsXuan, J., Pearson, R. B. & Sanij, E. (2020). CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer. MOLECULAR & CELLULAR ONCOLOGY, 7 (6), https://doi.org/10.1080/23723556.2020.1805256.
Access StatusOpen Access
Open Access at PMChttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671053
NHMRC Grant codeNHMRC/1162052
Acquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the efficacy of the novel drug CX-5461 in HGSOC is mediated through destabilization of DNA replication forks. The data highlights the potential of CX-5461 in overcoming a general mechanism of chemotherapeutic resistance.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References